We examined whether two functional polymorphisms (g.À1562C4T and g.À90(CA)14-24) in the matrix metalloproteinase (MMP)-9 gene or MMP-9 haplotypes affect the circulating levels of pro-MMP-9 and pro-MMP-9/TIMP-1 (tissue inhibitor of metalloproteinase-1) ratios in AIDS patients, and modulate alterations in these biomarkers after highly active antiretroviral therapy (HAART). We studied 82 patients commencing HAART. Higher pro-MMP-9 concentrations and pro-MMP-9/TIMP-1 ratios were found in CT/TT patients compared with CC patients. HAART decreased pro-MMP-9 levels and pro-MMP-9/TIMP-1 ratios in CT/TT patients, it did not modify pro-MMP-9 levels and it increased pro-MMP-9/TIMP-1 ratios in CC patients. The g.À90(CA)14-24 polymorphism, however, produced no significant effects. Moreover, we found no significant differences in HAARTinduced changes in plasma pro-MMP-9, TIMP-1 and pro-MMP-9/TIMP-1 ratios when different MMP-9 haplotypes were compared. These findings suggest that the g.À1562C4T polymorphism affects pro-MMP-9 levels in patients with AIDS and modulates the alterations in pro-MMP-9 levels caused by HAART, thus possibly affecting the risk of cardiovascular complications.
Introduction
It is widely acknowledged that the use of highly active antiretroviral therapy (HAART) has decreased the morbidity and mortality associated with AIDS.
Mounting evidence indicates that a family of structurally related, zinc-dependent enzymes, the matrix metalloproteinases (MMPs), play key roles in the pathogenesis of cardiovascular diseases. 12, 13 Specifically, MMP-2 and MMP-9 (gelatinase A and gelatinase B, respectively) play a role in many physiological processes, and increased expression and activity of these enzymes have been reported in a variety of pathological conditions, including cardiovascular diseases. 12 In support of this idea, recent studies have shown that the circulating levels of MMP-9 may be used as a bloodborne biochemical marker for cardiovascular diseases. 12, [14] [15] [16] Furthermore, MMP-9 plasma levels predicted mortality in patients with coronary artery disease. 12 Together, these findings suggest that plasma MMP-9 and MMP-2 may have diagnostic and prognostic value.
Importantly, recent studies have shown that MMPs, especially MMP-9, play a role in the pathophysiology of HIV complications. [17] [18] [19] [20] [21] Therefore, it is possible that the circulating levels of MMP-9 reflect the increased susceptibility to cardiovascular diseases in HIV patients.
MMP-9 activity is regulated at different levels, including its transcription, activation of latent forms of MMP (proenzyme) and inhibition by endogenous inhibitors, the tissue inhibitors of metalloproteinase (TIMPs). 22 In addition, genetic polymorphisms in the promoter region of the MMP-9 gene affect MMP-9 transcription. Although several polymorphisms in MMP-9 gene have already been identified, only two of them are known to be functional, a g.À1562C4T substitution (rs 3918242) and a microsatellite g.À90(CA)14-24 (rs 3222264). In vitro studies showed that the 'C' to 'T' substitution at À1562 position results in the loss of binding of a nuclear repressor protein, thus leading to increased MMP-9 expression. 23 The g.À90(CA)14-24 polymorphism, however, caused a 50% reduction in MMP-9 promoter activity when the (CA) 14 allele was compared with the (CA) 21 allele. 24 These polymorphisms have been associated with cardiovascular diseases. 12, 23, [25] [26] [27] [28] Therefore, our hypothesis was that these polymorphisms could interact with HIV infection or with HAART and modify MMP-9 levels in HIV patients, possibly affecting their cardiovascular risk.
Thus, the main objectives of this study were to determine whether the two MMP-9 polymorphisms mentioned above modulate the circulating levels of pro-MMP-9 in HIV patients, and whether these polymorphisms modify the alterations in pro-MMP-9 levels induced by HAART.
Results
The frequencies of C and T alleles for g.À1562C4T polymorphism were 90.9 and 9.1%, respectively, and the genotypes distribution was CC, 82.9%; CT, 15.9%; and TT, 1.2%. We classified the alleles for the microsatellite g.À90(CA)14-24 polymorphism as the low (L) count group when the number of CA repeats was less than 21, and as the high (H) count group when the number of CA repeats was 21 or more. The frequencies of the grouped alleles L and H were 48.2% and 51.8%, respectively, and the genotypes distribution was LL, 26.8%; LH, 50%; and HH, 23.2%. The distribution of genotypes for the two polymorphisms studied here showed no deviation from Hardy-Weinberg equilibrium (all P40.05). The estimated haplotypes frequencies for the whole group of patients are shown in Table 1 .
The zymographic analyses of gelatinolytic activity showed that gelatinolytic activity was completely inhibited by 5 mM EDTA or 1 mM 1,10-phenanthroline (data not shown), thus confirming the bands in the gel as MMP active.
Effects of MMP-9 polymorphisms on the circulating levels of pro-MMP-9 in HIV patients There were no significant differences in age, sex, body mass index, systolic and diastolic arterial blood pressure, heart rate, cholesterol, triglycerides, glycemia, viral load, leucocytes, neutrophils, platelets, pro-MMP-2 and ethnicity when HIV patients were compared according to their genotypes (Table 2 Higher pro-MMP-9 plasma levels and pro-MMP-9/TIMP-1 ratios were found in the CT/TT genotype group compared with the CC genotype group (Figure 1 ; panel a and c; Po0.05), whereas no significant differences were found in TIMP-1 concentrations ( Figure 1 ; panel b; P40.05). However, we found no significant differences in plasma pro-MMP-9, TIMP-1 or pro-MMP-9/TIMP-1 ratio among the different genotype groups of the microsatellite g.À90(CA)14-24 polymorphism (Figure 1 ; P40.05). We found no significant differences in plasma pro-MMP-9, TIMP-1 or pro-MMP-9/TIMP-1 ratio when the different MMP-9 haplotypes were compared (Figure 2 ; all P40.05).
Effects of MMP-9 polymorphisms on HAART-induced changes in circulating MMP-9 and TIMP-1 levels On taking into consideration the entire group of patients, we found that plasma pro-MMP-9 levels were not affected by HAART, although plasma TIMP-1 decreased (from 311.0 ± 22.6 to 206.0 ± 16.1; Po0.005) and pro-MMP-9/ TIMP-1 increased (from 0.29 ± 0.04 to 0.48 ± 0.07; Po0.05).
We found no significant changes in systolic and diastolic arterial blood pressure, triglycerides, leucocytes, 3.9 ± 0.1 3.9 ± 0.1 Matrix metalloproteinase 9 polymorphism and HIV therapy C Demacq et al neutrophils, lymphocytes and pro-MMP-2 after HAART (Table 3 ; all P40.05). However, body mass index, cholesterol, CD4 þ cells count, platelets and glycemia increased after HAART, whereas heart rate and viral load decreased (Table 3 ; all Po0.05). No significant differences were found when these changes were compared in different genotype groups (data not shown).
Although we found no significant changes in plasma pro-MMP-9 after HAART (Table 3 ; P40.05) on considering all HIV patients, significant differences were found when these patients were grouped according to their genotypes. HAART was associated with significant decreases in pro-MMP-9 levels in carriers of the T allele (CT or TT patients) (Figure 3a ; Po0.05) and with non-significant increases in CC genotype patients (Figure 3a ; P40.05). Conversely, HAART produced small increase in TIMP-1 concentrations in carriers of the T allele and significant decrease in CC patients (Figure 3b ; Po0.05). As a consequence of these genotype-dependent changes in pro-MMP-9 and TIMP-1 levels, HAART tended to decrease pro-MMP-9/TIMP-1 ratios in carriers of the T allele and increased pro-MMP-9/TIMP-1 ratios in CC genotype patients (Figure 3c ; Po0.05).
The microsatellite g.À90(CA)14-24 polymorphism, however, produced no significant effects on HAART-induced changes in plasma pro-MMP-9, TIMP-1 or pro-MMP-9/ TIMP-1 ratios (Figure 3 ; P40.05). Furthermore, we found no significant differences in HAART-induced changes in plasma pro-MMP-9, TIMP-1 or pro-MMP-9/TIMP-1 ratios when the different MMP-9 haplotypes were compared (Figure 4 ; P40.05).
Discussion
Although the mortality rates associated with AIDS decreased significantly after HAART, 1,2 the number of deaths caused by cardiovascular diseases increased in these patients. [4] [5] [6] 9, 10, 29, 30 Therefore, the study of mechanisms involved in HAART-associated cardiovascular mortality may be relevant for the development of new drugs to treat HIV infection. In this study, we showed for the first time that HAART decreases the circulating levels of TIMP-1 by approximately 65%, thus increasing pro-MMP-9/TIMP-1 ratios by 34%. Although these findings should be interpreted with caution because we missed a control (placebotreated) group for ethical reasons, the increase in pro-MMP-9/TIMP-1 ratio is consistent with an increased net MMP-9 activity after HAART, even though the pro-MMP-9 levels were not affected by HAART. This suggestion is based on the fact that TIMP-1 is a major endogenous inhibitor of MMP-9, 31 and the pro-MMP-9/TIMP-1 ratios may offer a better index of MMP-9 activity in vivo than the simple measurement of MMP-9 levels. However, the increased pro-MMP-9/TIMP-1 ratios after HAART apparently contrast with earlier reports on how antiretrovirals may affect MMP-9. For example, antiretroviral therapy reduced the capacity of peripheral-blood mononuclear cells to secrete MMP-9 in HIV-infected patients, 32 and zidovudine and indinavir attenuated the increase in MMP-9 expression induced by exposure of both astrocytes and microglia to lipopolysaccharide. 33 It is possible that major methodological differences between these studies and the present study may explain the apparently conflicting findings. The increased pro-MMP-9/TIMP-1 ratios after HAART suggest that HAART increases the cardiovascular risk of AIDS patients through mechanisms involving MMP-9, as suggested by a number of studies showing that net MMP-9 activity levels are associated with cardiovascular diseases and increased cardiovascular risk. 12, 14, 15, 34, 35 The lack of significant effects associated with the g.À90(CA)14-24 polymorphism suggests that this polymorphism does not play a major role in the alterations associated with HIV infection. In addition, we found no significant effects of MMP-9 haplotypes on the circulating levels of pro-MMP-9, TIMP-1 or pro-MMP-9/TIMP-1 ratio. Although haplotype analysis has been valued as a more powerful approach than the analysis of single ) is used to normalize the data between the gels. In the molecular weight (MW) lane, it is human blood that contains the 92-kDa-pro-MMP-9 (monomeric form) band and the 72-kDa-pro-MMP-2 band (a). Plasma pro-MMP-9 (b) and tissue inhibitor of metalloproteinase (TIMP)-1 levels (c), and MMP-9/TIMP-1 ratio (d) in the three haplotype groups (the H4 group had only one patient). The bar shows the median value.
Matrix metalloproteinase 9 polymorphism and HIV therapy C Demacq et al polymorphisms, 36, 37 it may be less informative when a causal connection between genetic variations and a phenotype is truly driven by a single polymorphism. 38 This may well be the case of this study. However, the relatively small number of patients included in this study (n ¼ 82) may have limited the power to detect significant effects associated with rare alleles or haplotypes.
A third major finding reported herein is that the g.À1562C4T polymorphism affects HAART-induced alterations in pro-MMP-9, TIMP-1 or pro-MMP-9/TIMP-1 ratio. Interestingly, HAART decreased pro-MMP-9 levels in CT/TT patients and caused small non-significant increases in CC patients. These genotype-dependent effects were associated with increased TIMP-1 concentrations in CT/TT patients and with major decreases in TIMP-1 concentrations in CC patients. Although this polymorphism was associated with a trend for lower pro-MMP-9/TIMP-1 ratios in CT/TT patients, significant increases in pro-MMP-9/TIMP-1 ratios were found in CC patients, thus suggesting that CC patients but not CT/TT patients, are at higher risk of MMP-9-associated increases in cardiovascular risk after HAART. The g.À90(CA)14-24 polymorphism and MMP-9 haplotypes, however, were not associated with significant effects on HAART-induced changes in plasma pro-MMP-9, TIMP-1 or pro-MMP-9/TIMP-1 ratios. Together, these results suggest that the g.À1562C4T polymorphism modifies the alterations in net MMP-9 levels induced by HAART. However, whether this polymorphism affects the incidence of clinical events in AIDS patients remains to be determined.
The findings reported here should be interpreted with caution. The main hypothesis of this study was that the two functional MMP-9 polymorphisms could interact with HIV infection or with HAART and modify MMP-9 levels in HIV patients. However, some of the positive findings reported here may not resist statistical correction for multiple testing. This is the case of the pro-MMP-9/TIMP-1 ratio in HIV patients before HAART. This limitation results from the fact that we studied a relatively small number of patients. A more powerful study should be carried out to confirm our findings. In addition, we have not examined whether the MMP-9 polymorphisms studied here affect the incidence of clinical events in AIDS patients. This issue remains to be determined and should be addressed in further studies.
In conclusion, our results show that the MMP-9 g.À1562C4T polymorphism affects the circulating levels of pro-MMP-9 and the MMP-9/TIMP-1 ratios in AIDS patients, as well as the HAART-induced alterations in these biomarkers. Although patients with the CT/TT genotypes for this polymorphism may be at an increased risk of developing cardiovascular complications associated with AIDS, patients with the CC genotype are probably at an increased risk of developing cardiovascular complications after HAART. A further study examining whether this polymorphism is a marker of variable susceptibility to clinical events is warranted. We studied 82 HIV patients from our tertiary-care general hospital. These patients were first started on HAART with zidovudine, lamivudine and efavirenz. This specific drug combination was chosen on the basis of therapeutic protocols recommended by the Brazilian Ministry of Health. After written, informed consent were obtained, we drew 5 ml of venous blood samples, which were collected before and 3-4 months after HAART in standard vacutainer tubes (Becton-Dickinson, Sao Paulo, Brazil) containing sodium/ potassium EDTA as anticoagulant. Plasma samples were separated and stored at À70 1C until assayed for MMPs and TIMPs measurements. Genomic DNA was extracted from the cellular component of 1 ml of whole blood by a saltingout method and stored at À20 1C until analyzed.
Genotyping
Genotypes for the g.À1562C4T polymorphism were determined by polymerase chain reaction (PCR) amplification using the primers 5 0 -GCC TGG CAC ATA GTA GGC CC-3 0 (sense) and 5 0 -CTT CCT AGC CAG CCG GCA TC-3 0 (antisense) and PCR conditions as described earlier. 39, 40 The amplified products were digested with SphI (New England Biolabs, Ipswich, MA, USA) overnight at 37 1C, producing fragments of 247 and 188 bp in the case of a polymorphic variant (allele T), or an undigested 435-bp band in the case of a wild-type allele (allele C). Fragments were separated by electrophoresis in 12% polyacrylamide gels and visualized by silver staining.
To determine the genotypes for the g.À90(CA)14-24 polymorphism, a PCR was carried out using the primers 5 0 -GAC TTG GCA GTG GAG ACT GCG GGC A-3 0 (sense) and 5 0 -GAC CCC ACC CCT CCT TGA CAG GCA A-3 0 (antisense). 40 The PCR conditions were maintained as described earlier 40 and the amplified products were separated in a 7% polyacrylamide-urea gel and visualized by silver staining. Differences in molecular weight (or number of bases) from 146 bp (CA 14 repeats) to 166 bp (CA 24 repeats) were determined by comparison with migration of a 10-bp DNA ladder (Invitrogen, Carlsbad, CA, USA) and with some samples from homozygotes that were sequenced. The alleles for the microsatellite g.À90(CA)14-24 polymorphism were classified as 'low' (L) count when the number of CA repeats was less than 21 and as 'high' (H) count when the number of CA repeats was 21 or more.
SDS-polyacrylamide gel electrophoresis (PAGE) gelatin zymography
Gelatin zymography of MMP-2 and MMP-9 from plasma was carried out as described earlier. 41, 42 This assay allows the identification of the pro forms of MMP-2 and MMP-9. 43 Briefly, plasma samples were subjected to electrophoresis on 7% SDS-PAGE co-polymerized with gelatin (1%) as the substrate. After electrophoresis was complete, the gel was incubated for 1 h at room temperature in a 2% Triton X-100 solution and incubated at 37 1C for 16 h in Tris-HCl buffer, pH 7.4, containing 10 mmol l À1 CaCl 2 . The gels were stained with 0.05% Coomassie brilliant blue G-250 and then destained with 30% methanol and 10% acetic acid. Gelatinolytic activities were detected as unstained bands against the background of Coomassie blue-stained gelatin. Enzyme activity was assayed by densitometry using a Kodak Electrophoresis Documentation and Analysis System (EDAS) 290 (Kodak, Rochester, NY, USA). 44 The pro forms of MMP-2 and MMP-9 were identified as bands at 72 and 92 kDa, respectively, using the relation of log Mr to the relative mobility of Sigma SDS-PAGE LMW marker proteins (Sigma, St Louis, MO, USA).
Enzyme immunoassays of TIMP-1
The plasma concentrations of TIMP-1 were measured with a commercially available enzyme-linked immunosorbent assay kit (Amersham Biosciences UK Limited, Buckinghamshire, UK) according to manufacturer's instructions.
Haplotype inference
Haplotypes were inferred using the Bayesian statistical based program PHASE version 2.1 (http://www.stat.washington. edu/stephens/software.html) 45 to estimate the haplotype frequencies in the population and the two haplotypes for each subject (Table 1) . These results were used to evaluate a possible relationship between haplotypes and plasma pro-MMP-9 levels. The possible haplotypes including genetic variants for the two MMP-9 polymorphisms studied (H or L variants for g.À90(CA)14-24 and C or T variants for the g.À1562C4T) were H1 (HC), H2 (HT), H3 (LC) and H4 (LT).
Statistical analysis
The results are expressed as means±s.e.m. The distribution of genotypes for each polymorphism was assessed for deviation from the Hardy-Weinberg equilibrium by using chi-squared tests (StatView, Cary, NC, USA). Owing to of the relatively low frequency of the TT genotype, we combined both TT and CT genotypes into one group (CT þ TT group) and compared with the CC genotype group. The two genotype groups were evaluated for differences in demographic data and plasma MMPs and TIMP-1 levels using the Mann-Whitney test. The microsatellite (CA) n genotype groups (LL, LH and HH) and haplotype groups were evaluated by Kruskal-Wallis test followed by the Dunn's multiple comparison test. A P-value less than 0.05 was considered to be statistically significant.
